IL-4Rα, is a shared subunit of the type I (IL-4) and type II (IL-4/IL-13) cytokine receptors. Blocking IL-4Rα with rademikibart disrupts downstream JAK/STAT signaling, reducing the differentiation of Th2 cells, IgE production, eosinophil recruitment, and epithelial inflammation — thereby addressing the underlying pathology of type 2 inflammatory diseases.